Treatment Related to Antihistamines
common.study.values.description
“Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines”
This is a multicenter, randomized, double-blind and placebo-controlled phase 2b dose-finding study to assess the efficacy and safety of LOU064 in adults chronic spontaneous urticaria (CSU) patients inadequately controlled by H1-antihistamines
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - LOU064 Arm 1
Low dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
Drug - LOU064 Arm 2
Medium dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
Drug - LOU064 Arm 3
High dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
Drug - LOU064 Arm 4
Low dose of LOU064 orally, twice daily from Day 1 to 85
Drug - LOU064 Arm 5
Medium dose of LOU064 orally, twice daily from Day 1 to 85
Drug - LOU064 Arm 6
High dose of LOU064 orally, twice daily from Day 1 to 85
Drug - Placebo arm
Matching placebo, orally, twice daily from Day 1 to 85
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Multicenter, Randomized, Double-blind, Placebo- Controlled Phase 2b Dose-finding Study to Investigate the Efficacy, Safety and Tolerability of LOU064 in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines
common.study.values.clinical-trial-id
NCT03926611
participant.views.study.view.id
dG6E5b
